Calciject 40 CM Solution for Injection

国家: 英国

语言: 英文

来源: VMD (Veterinary Medicines Directorate)

有效成分:

Boric Acid, Calcium, Magnesium

可用日期:

Norbrook Laboratories Limited

ATC代码:

amended

INN（国际名称）:

Boric Acid, Calcium, Magnesium

药物剂型:

Solution for injection

处方类型:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

治疗组:

Cattle

治疗领域:

Mineral

授权状态:

Authorized

授权日期:

1994-07-05

产品特点

Revised: July 2010
ATCVet code amended
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Calciject 40 CM Solution For Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Contains Calcium Borogluconate
40% w/v
Magnesium Hypophosphite Hexahydrate
5% w/v
Each 400ml contains :
11.9g calcium (provided by calcium gluconate and calcium
borogluconate)
1.85g magnesium (provided by magnesium hypophosphite).
Also contains 6.84% w/v boric acid.
EXCIPIENTS:
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for Injection
A clear pale yellow solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Indicated in the treatment of hypocalcaemia in cattle where increased
blood
magnesium levels are required.
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
Revised: July 2010
ATCVet code amended
2
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
The solution should be warmed to body temperature before
administration. Intravenous injections should be given slowly in order
to
avoid possible neuromuscular dysfunction and cardiac insufficiency.
Normal aseptic precautions should be observed.
Sites of subcutaneous administration should be massaged gently.
ii.
Special precautions to be taken by the person administering the
veterinary
medicinal product to animals
Care should be taken to avoid accidental self-injection: may cause
irritation at site of injection.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Occasional temporary swelling may occur at sites of subcutaneous
administration.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
Safe for use during pregnancy and lactation
4.8
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None
4.9
AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Administer by subcutaneous or slow intravenous injection
Cattle:200 to 400 ml
4.10
OVERDOSE (SYMPTOMS, EMERGENCY PROCEDURES, ANTIDOTES), IF NECESSAR